These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31848189)

  • 1. A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors.
    Varga A; Soria JC; Hollebecque A; LoRusso P; Bendell J; Huang SA; Wagle MC; Okrah K; Liu L; Murray E; Sanabria-Bohorquez SM; Tagen M; Dokainish H; Mueller L; Burris H
    Clin Cancer Res; 2020 Mar; 26(6):1229-1236. PubMed ID: 31848189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.
    Moschos SJ; Sullivan RJ; Hwu WJ; Ramanathan RK; Adjei AA; Fong PC; Shapira-Frommer R; Tawbi HA; Rubino J; Rush TS; Zhang D; Miselis NR; Samatar AA; Chun P; Rubin EH; Schiller J; Long BJ; Dayananth P; Carr D; Kirschmeier P; Bishop WR; Deng Y; Cooper A; Shipps GW; Moreno BH; Robert L; Ribas A; Flaherty KT
    JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.
    Falchook GS; Kurzrock R; Amin HM; Xiong W; Fu S; Piha-Paul SA; Janku F; Eskandari G; Catenacci DV; Klevesath M; Bruns R; Stammberger U; Johne A; Bladt F; Friese-Hamim M; Girard P; El Bawab S; Hong DS
    Clin Cancer Res; 2020 Mar; 26(6):1237-1246. PubMed ID: 31822497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.
    Sullivan RJ; Infante JR; Janku F; Wong DJL; Sosman JA; Keedy V; Patel MR; Shapiro GI; Mier JW; Tolcher AW; Wang-Gillam A; Sznol M; Flaherty K; Buchbinder E; Carvajal RD; Varghese AM; Lacouture ME; Ribas A; Patel SP; DeCrescenzo GA; Emery CM; Groover AL; Saha S; Varterasian M; Welsch DJ; Hyman DM; Li BT
    Cancer Discov; 2018 Feb; 8(2):184-195. PubMed ID: 29247021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
    Sarker D; Ang JE; Baird R; Kristeleit R; Shah K; Moreno V; Clarke PA; Raynaud FI; Levy G; Ware JA; Mazina K; Lin R; Wu J; Fredrickson J; Spoerke JM; Lackner MR; Yan Y; Friedman LS; Kaye SB; Derynck MK; Workman P; de Bono JS
    Clin Cancer Res; 2015 Jan; 21(1):77-86. PubMed ID: 25370471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.
    Rosen LS; LoRusso P; Ma WW; Goldman JW; Weise A; Colevas AD; Adjei A; Yazji S; Shen A; Johnston S; Hsieh HJ; Chan IT; Sikic BI
    Invest New Drugs; 2016 Oct; 34(5):604-13. PubMed ID: 27424159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
    Shapiro GI; LoRusso P; Cho DC; Musib L; Yan Y; Wongchenko M; Chang I; Patel P; Chan IT; Sanabria-Bohorquez S; Meng RD; Bendell JC
    Invest New Drugs; 2021 Feb; 39(1):163-174. PubMed ID: 32737717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours.
    Tolcher A; Goldman J; Patnaik A; Papadopoulos KP; Westwood P; Kelly CS; Bumgardner W; Sams L; Geeganage S; Wang T; Capen AR; Huang J; Joseph S; Miller J; Benhadji KA; Brail LH; Rosen LS
    Eur J Cancer; 2014 Mar; 50(5):867-75. PubMed ID: 24440085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
    Shapiro GI; LoRusso P; Kwak E; Pandya S; Rudin CM; Kurkjian C; Cleary JM; Pilat MJ; Jones S; de Crespigny A; Fredrickson J; Musib L; Yan Y; Wongchenko M; Hsieh HJ; Gates MR; Chan IT; Bendell J
    Invest New Drugs; 2020 Apr; 38(2):419-432. PubMed ID: 31020608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors.
    Weekes C; Lockhart A; LoRusso P; Murray E; Park E; Tagen M; Singh J; Sarkar I; Mueller L; Dokainish H; Shapiro G; Burris H
    Oncologist; 2020 Oct; 25(10):833-e1438. PubMed ID: 32311798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
    Weekes CD; Von Hoff DD; Adjei AA; Leffingwell DP; Eckhardt SG; Gore L; Lewis KD; Weiss GJ; Ramanathan RK; Dy GK; Ma WW; Sheedy B; Iverson C; Miner JN; Shen Z; Yeh LT; Dubowy RL; Jeffers M; Rajagopalan P; Clendeninn NJ
    Clin Cancer Res; 2013 Mar; 19(5):1232-43. PubMed ID: 23434733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma.
    Wen PY; Cloughesy TF; Olivero AG; Morrissey KM; Wilson TR; Lu X; Mueller LU; Coimbra AF; Ellingson BM; Gerstner E; Lee EQ; Rodon J
    Clin Cancer Res; 2020 Apr; 26(8):1820-1828. PubMed ID: 31937616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
    Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
    Martinez-Garcia M; Banerji U; Albanell J; Bahleda R; Dolly S; Kraeber-Bodéré F; Rojo F; Routier E; Guarin E; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Soria JC
    Clin Cancer Res; 2012 Sep; 18(17):4806-19. PubMed ID: 22761467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.
    Dolly SO; Wagner AJ; Bendell JC; Kindler HL; Krug LM; Seiwert TY; Zauderer MG; Lolkema MP; Apt D; Yeh RF; Fredrickson JO; Spoerke JM; Koeppen H; Ware JA; Lauchle JO; Burris HA; de Bono JS
    Clin Cancer Res; 2016 Jun; 22(12):2874-84. PubMed ID: 26787751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
    Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
    Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
    Jamieson D; Griffin MJ; Sludden J; Drew Y; Cresti N; Swales K; Merriman M; Allen R; Bevan P; Buerkle M; Mala C; Coyle V; Rodgers L; Dean E; Greystoke A; Banerji U; Wilson RH; Evans TR; Anthoney A; Ranson M; Boddy AV; Plummer R
    Eur J Cancer; 2016 Nov; 68():1-10. PubMed ID: 27693888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
    Britten CD; Adjei AA; Millham R; Houk BE; Borzillo G; Pierce K; Wainberg ZA; LoRusso PM
    Invest New Drugs; 2014 Jun; 32(3):510-7. PubMed ID: 24395457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
    Wicki A; Brown N; Xyrafas A; Bize V; Hawle H; Berardi S; Cmiljanović N; Cmiljanović V; Stumm M; Dimitrijević S; Herrmann R; Prêtre V; Ritschard R; Tzankov A; Hess V; Childs A; Hierro C; Rodon J; Hess D; Joerger M; von Moos R; Sessa C; Kristeleit R
    Eur J Cancer; 2018 Jun; 96():6-16. PubMed ID: 29660598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.
    Jänne PA; Cohen RB; Laird AD; Macé S; Engelman JA; Ruiz-Soto R; Rockich K; Xu J; Shapiro GI; Martinez P; Felip E
    J Thorac Oncol; 2014 Mar; 9(3):316-23. PubMed ID: 24496004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.